Medicenna Therapeutics Corp. · TSX:MDNA
Medicenna Therapeutics — ESMO-IO Congress 2025
27 slides from Medicenna Therapeutics's conference presentation, Dec 10, 2025
Slide 1: Company Presentation & KOL Webinar MDNA11 Clinical Data Update
Company Presentation & KOL Webinar MDNA11 Clinical Data Update 10 December 2025 ESMO-IO Congress 2025
Slide 2: Disclaimer
Disclaimer Certain statements in this presentation may constitute “forward-looking statements” under applicable securities laws. These forward-looking statements include, but are not limited to, information about possible or assumed future results of the Medicenna Therapeutics Corp’s (the “Company”
Slide 3: Today's Agenda
Today’s Agenda 1. Introduction & MDNA11 Overview 2. ABILITY-1 Phase 1/2 Data Presented at ESMO-IO 2025 Congress 3. Principal Investigator Perspectives 4. KOL Commentary 5. Q&A 2025 MEDICENNA THERAPEUTICS 3
Slide 4: On Today's Call
On Today’s Call Dr. Fahar Merchant Dr. Arash Yavari Dr. André Mansinho David Hyman PhD MBBS PhD MD MSc CA CBV President & CEO Director of Clinical Principal Investigator Chief Financial Officer Strategy University of Oxford University of Lisbon KOL Commentary: • Dr. Hussein Tawbi, MD PhD, MD Anderso
Slide 5: MDNA11 Overview
MDNA11 Overview • A ‘β-enhanced, not-α’ IL-2 superagonist in clinical development for advanced solid tumors • Clinical-Stage Therapy in Phase 1/2 with a Monotherapy Treatment Arm and a Combination Arm with KEYTRUDA® (pembrolizumab) This study is in collaboration with Merck Sharp & Dohme LLC, a subsi
Slide 6: MDNA11: A Unique 'β-enhanced Not-α' IL-2 Albumin-fused Superkine
MDNA11: A Unique ‘β-enhanced Not-α’ IL-2 Albumin-fused Superkine Superior ‘β-enhanced’ MDNA11, the Only “β-enhanced not- Enhanced PK properties α”Albumin-fused IL-2 receptor selectivity Human Albumin • β-enhanced (30× increase in affinity): Selective CD8⁺ T and NK cell activation and proliferation E
Slide 7: Clinical Data Update
Clinical Data Update • ABILITY-1 Phase 1/2 Data Presented at ESMO-IO 2025 Congress
Slide 8: ABILITY-1: FIH Trial of MDNA11 in Patients with Advanced Solid Tumors
ABILITY-1: FIH Trial of MDNA11 in Patients with Advanced Solid Tumors MDNA11 Monotherapy MDNA11 + Pembrolizumab Phase 1: Dose Phase 2: Dose Expansion Phase 1: Dose Phase 2: Dose Expansion Escalation / Evaluation (advanced ICI resistant tumors) Escalation / Evaluation (advanced ICI resistant tumors)
Slide 9: Patient Baseline Characteristics
Patient Baseline Characteristics Monotherapy Combination Therapy Baseline Characteristics (N = 61) (N = 50) Age, median years (range) 63 (27, 85) 63 (31, 76) Male, N (%) 35 (57.4%) 20 (40.0%) 0 40 (65.6%) 25 (50.0%) ECOG, N (%) 1 21 (34.4%) 25 (50.0%) 1-3L 46 (75.4%) 29 (58.0%) Prior Lines of Therap
Slide 10: Patients with 29 Different Advanced Stage Solid Cancers Enrolled
Patients with 29 Different Advanced Stage Solid Cancers Enrolled Response achieved in 7 tumor types Created in https://BioRender.com cSCC, cutaneous squamous cell carcinoma; TNBC, triple-negative breast cancer;ccRCC, clear cell renal cell carcinoma; NSCLC, non–small cell lung cancer; SCLC, small cel
Slide 11: Summary of Monotherapy and Combination Therapy Safety
Summary of Monotherapy and Combination Therapy Safety Monotherapy (N = 61) Combination (N = 50) • No DLTs in monotherapy or combination therapy up to 120 µg/kg • >90% TRAEs Grade 1–2 and transient, resolving by 48 hours • Grade 3–4 mainly laboratory abnormalities without clinical sequelae • Single t
Slide 12: Durable Single Agent Activity in Phase-2 Eligible Expansion Cohorts
Durable Single Agent Activity in Phase-2 Eligible Expansion Cohorts MDNA11 ≥ 60 µg/kg New lesions developed and stabilized; shrinkage of target lesions by >80% * Off-treatment remission for >7 months Cutaneous Melanoma (ICI 2º Resistance) 7-week Complete Tumor treatment break Regression RTx PDAC Off
Slide 13: Single-agent activity in Phase 2–eligible expansion cohorts
Single-agent activity in Phase 2–eligible expansion cohorts Cutaneous melanoma Secondary ICI resistance: Cutaneous Melanoma (N = 8) • ORR of 37.5% (1 CR + 2 PRs) TMB-H (N = 5) Best Change from Baseline (%) • DCR of 75% (1 CR + 2 PRs + 3 SD) MSI-H/dMMR (N = 9) • Tumor regression in 6 of 8 (75%) patie
Slide 14: Monotherapy efficacy in ICI-resistant cancers
Monotherapy efficacy in ICI-resistant cancers Case 1 Case 2 Case 3 Case 4 Case 5 Tumor Cutaneous Melanoma Cutaneous Melanoma Cutaneous Melanoma MSI-H PDAC MSI-H PDAC Age (yr) 62 64 56 55 85 Tumor Mutation(s) BRAF T599dup BRAF V600K NRAS Mutation − − Nivolumab Nivolumab Prior ICI Pembrolizumab Pembro
Slide 15: Encouraging Clinical Activity in Combination Phase 2–Eligible Expansion Cohorts
Encouraging Clinical Activity in Combination Phase 2–Eligible Expansion Cohorts MDNA11 ≥60 µg/kg (Q2W/Q3W) + 400 mg pembrolizumab (Q6W) Deepening tumor response MSS Endometrial (–36%) at week 49 (>10 wks (ICI 2º Resistance) after end of treatment) Cutaneous PR Melanoma SD iUPD RCC Endometrial iCPD/P
Slide 16: Encouraging Clinical Activity with MDNA11 + Pembrolizumab in Phase 2–Eligible Expansion Cohorts
Encouraging Clinical Activity with MDNA11 + Pembrolizumab in Phase 2–Eligible Expansion Cohorts Microsatellite-stable Endometrial Best Change from Baseline (%) Cancer (ICI 2º Resistance): MDNA11 ≥60 µg/kg (Q2W/Q3W) + 400 mg 1 pembrolizumab (Q6W) • ORR of 50% (2 PRs) • DCR of 75% (2 PRs + 1 SD) TMB-H
Slide 17: Combination Efficacy in ICI-Resistant/Ineligible Cancer
Combination Efficacy in ICI-Resistant/Ineligible Cancer Case 8 Case 1 Case 2 Case 3 Case 4 Case 5 Case 6 Case 7 (roll-over)* TMB-H Breast TMB-H CRC MSS MSS Cutaneous TMB-H NET Tumor MSI-H CRC SCC anal (22 mut/Mb) (67 mut/Mb) Endometrial Endometrial Melanoma Bladder Age (yr) 60 51 63 67 75 43 70 53 P
Slide 18: Disease Control with MDNA11 is Associated with Significantly Prolonged Overall Survival
Disease Control with MDNA11 is Associated with Significantly Prolonged Overall Survival Patients enrolled in monotherapy and combination in all tumor types treated with ≥ 60 µg/kg MDNA11 p = 0.0023 p = 0.0138 HR: 0.288 (95% CI: 0.125-0.663) HR: 0.278 (95% CI: 0.02-0.845) mOS: not reached mOS: 120.2
Slide 19: Robust Expansion of Effector and Stem-like CD8+ T Cells
Robust Expansion of Effector and Stem-like CD8+ T Cells Peak CD8+ T cell response in peripheral blood at 90 µg/kg MDNA11 Effector CD8+ T cells Stem-like CD8+ T cells Monotherapy Combination Therapy Monotherapy Combination Therapy p < 0.0001 p < 0.0001 p < 0.0005 p < 0.0001 Statistics using paired t-
Slide 20: MDNA11 in Advanced Solid Tumors: Key Takeaways
MDNA11 in Advanced Solid Tumors: Key Takeaways Manageable safety profile: No DLTs observed in any cohort. >90% TRAEs were grade 1-2 and transient Biological Effective Dose Range (BEDR): Preliminary recommended dose for expansion (pRDE) for monotherapy and combination arms was established at 90 ug/kg
Slide 21: Principal Investigator Perspectives
Principal Investigator Perspectives
Slide 22: KOL Commentary
EDIC ENNA KOL Commentary
Slide 23: Q&A
EDIC ENNA Q&A
Slide 24: Supplementary Data
Supplementary Data 2025 MEDICENNA THERAPEUTICS
Slide 25: ORR in Phase 2 Eligible Monotherapy and Combination Expansion Cohorts
ORR in Phase 2 Eligible Monotherapy and Combination Expansion Cohorts MDNA11 Monotherapy MDNA11 + Pembrolizumab Cutaneous Melanoma MSI-H Tumors Endometrial TMB-H Tumors (ICI 2º resistance) (ICI experienced) (ICI 2º resistance) 37.5% (3/8) 22.2 % (2/9) 50.0% (2/4) 25.0% (2/8) ORR [95% CI: 13.7-69.4]
Slide 26: Tumor Regression in 50% of Monotherapy Roll Over Patients
Tumor Regression in 50% of Monotherapy Roll Over Patients BOR on MDNA11 Monotherapy SD PD PD SD PD PR Re-staged Baseline (%) Best Change from PR MSI-H CRC (+) Cervical (+) TMB-H NET Bladder MSI-H Ovarian MSI-H Gastric (+) cMelanoma (+) Data cut-off: Dec. 1, 2025 CRC, colorectal cancer; NET, neuroend
Slide 27: Sustained Expansion and Activation of CD8+ T and NK Cells
Sustained Expansion and Activation of CD8+ T and NK Cells Data from Day 8 of each cycle 2025 MEDICENNA THERAPEUTICS 27